UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients.
about
Direct-acting antivirals for the treatment of chronic hepatitis C: open issues and future perspectivesΜanagement of patients with hepatitis B and C before and after liver and kidney transplantationManagement of patients with hepatitis B in special populationsPrior to the oral therapy, what do we know about HCV-4 in Egypt: a randomized survey of prevalence and risks using data mining computed analysis.Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality.IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients.Peg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: a meta-analysis on the role of response predictorsTreatment of chronic hepatitis C in liver transplant candidates and recipients: Where do we stand?Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir.Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines.Low rates of sustained virologic response with peginterferon plus ribavirin for chronic hepatitis C virus infection in HIV infected patients in Rio de Janeiro, Brazil.Cirrhosis and rapid virological response to peginterferon plus ribavirin determine treatment outcome in HCV-1 IL28B rs12979860 CC patients.Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the FutureA real-world intention-to-treat analysis of a decade's experience of treatment of hepatitis C with interferon-based therapies.Chronic hepatitis C genotype 1 virus: who should wait for treatment?Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C.Safety of telaprevir for chronic hepatitis C virus infection: a meta-analysis of randomized controlled trials.Boceprevir and personalized medicine in hepatitis C virus infectionBoceprevir: a review of its use in the management of chronic hepatitis C genotype 1 infection.Protease inhibitors for hepatitis C: economic implications.The clinical significance of drug-drug interactions in the era of direct-acting anti-viral agents against chronic hepatitis C.Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: a meta-analysis.The cost-effectiveness of boceprevir for hepatitis C.Review article: 2014 UK consensus guidelines - hepatitis C management and direct-acting anti-viral therapy.Hepatitis C virus genotype 3: a genotype that is not 'easy-to-treat'.No one size fits all-Shortening duration of therapy with direct-acting antivirals for hepatitis C genotype 1 infection.Safety of direct antiviral agents in the management of hepatitis C.HCV genotype 1 subtypes (1a and 1b): similarities and differences in clinical features and therapeutic outcome.Checkmate to liver biopsy in chronic hepatitis C?Comparative safety study on severe anemia by simeprevir versus telaprevir-based triple therapy for chronic hepatitis C.New developments in the management of hepatitis C virus infection: focus on boceprevir.Rates and predictors of response to anti-viral treatment for hepatitis C virus in HIV/HCV co-infection in a nationwide study of 619 patients.Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study.Are metabolic factors still important in the era of direct antiviral agents in patients with chronic hepatitis C?Focusing on the patient: impact of new UK guidelines on treatment of chronic hepatitis C.Despite poor interferon response in advanced hepatitis C virus infection, models of protease inhibitor treatment predict maximum treatment benefit.Hepatitis C therapy at home: a hospital and home care partnership.Quality indicators as a tool in improving the introduction of new medicines.
P2860
Q21265028-D1EC6C31-0A81-4786-946E-1366721D186FQ26864647-4E3C273C-3594-4D5B-B271-6839CC7569E6Q27016136-B48521B9-3A31-45EE-AE62-52507F9F15CAQ30881190-529161F7-08C7-4BC4-94EA-E8CA9AFA27B6Q34028307-87567683-B400-49C9-A944-F0ABE8B3AE9BQ34255562-4207BE3F-BBC7-4873-929F-1C83490AD1F2Q35146790-FBE0B917-F248-469B-AB2C-265AB064AAC7Q35790393-61BAF16C-5BD6-4D1C-8CCE-99AF66913EA4Q35928048-7E6200D0-DF83-4B73-8B10-4F37122FD6A5Q36973392-DE5977A9-B8AB-4923-99DE-0853AA657D13Q36997245-4234E2F5-E285-4681-9088-898DC0D726D8Q37044222-EA9688CC-CFE5-4268-9E8A-453B6CE1D622Q37135584-D556AF37-0AAE-43D1-9440-620319BED46BQ37279260-9D47B798-E487-4B1A-B146-06A9137EE918Q37654449-A9F55EFE-4C47-4577-B936-7B5A93CF616DQ37996076-9271716C-B19A-4C48-A0A1-5FB3FEA99307Q38034258-9CDD1125-DC70-4310-AF93-044E77DBDB90Q38066185-2B502D70-C999-4660-922D-55739283DF4DQ38066535-33620814-CAD6-45D5-B0A2-3ADA03FF30B9Q38120496-D2AFE8C2-8B23-40CC-B1BD-9689B6ECDF04Q38152774-FB28D6B8-00D7-4324-8F31-4F6D3ED11231Q38162979-BFB12336-07A0-42A9-BF6B-6ED7EB61B149Q38202682-4824EC73-6963-459A-9231-89B32C1DF19BQ38206215-A491D270-77FF-43F2-9870-73A145630245Q38249236-4E5ECCF7-D1FB-420F-9055-77D9B824E4E0Q38743836-F6CCB863-45DB-4ED4-A1AD-E477E944973CQ38818416-BB2F5044-7C53-43BB-B8AB-7BCAF7D7748FQ41412082-D824C897-85F2-4CAF-91A9-FAE4330C151AQ41678369-31123BFE-EF86-48C3-8883-611EA366E4F2Q42154570-E63213C4-5751-4D6B-A158-70DC90CF1E88Q42200489-3DFCC79F-47A7-4433-B689-F25F06D0E0A3Q42262341-4EB76513-B252-4987-A630-307E70218D3DQ42264411-DC555115-A924-4309-A1A5-ED7E7F1836A8Q42919523-4164A5A4-35EA-40D3-967F-9E06A37CA3C5Q42980742-80331E76-CBCD-4FE6-9E55-3EA74FC62B00Q42983413-988F6583-1BCB-4707-81D7-5AFBF592B7AFQ43406527-1D8EB7D0-BD46-422F-9D14-1003CEE3B155Q44695835-538E8C16-BE4E-441C-AA9F-A4CDB3B17660
P2860
UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
UK consensus guidelines for th ...... hepatitis C infected patients.
@en
UK consensus guidelines for th ...... hepatitis C infected patients.
@nl
type
label
UK consensus guidelines for th ...... hepatitis C infected patients.
@en
UK consensus guidelines for th ...... hepatitis C infected patients.
@nl
prefLabel
UK consensus guidelines for th ...... hepatitis C infected patients.
@en
UK consensus guidelines for th ...... hepatitis C infected patients.
@nl
P2093
P2860
P1476
UK consensus guidelines for th ...... hepatitis C infected patients.
@en
P2093
D J Mutimer
G R Foster
J F Dillon
P2860
P304
P356
10.1111/J.1365-2036.2012.04992.X
P407
P577
2012-02-01T00:00:00Z